Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 11, 2007, Pages 1929-1935

  Kuzuya, Teiji ^a,b   Katano, Yoshiaki ^a   Kumada, Takashi ^b   Toyoda, Hidenori ^b   Nakano, Isao ^a   Hirooka, Yoshiki ^a   Itoh, Akihiro ^a   Ishigami, Masatoshi ^a   Hayashi, Kazuhiko ^a   Honda, Takashi ^a   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Lamivudine; Recurrence; Survival

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; LIVER RESECTION; MALE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

EID: 34948823817     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04707.x     Document Type: Article

References (27)

1. Kumada T, Nakano S, Takeda I et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997 25 : 87 92.
2. Ou DP, Yang LY, Huang GW, Tao YM, Ding X, Chang ZG. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV. World J. Gastroenterol. 2005 11 : 2061 6.
3. Lin SM, Lin CJ, Hsu CW et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004 100 : 376 82.
4. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J. Gastroenterol. 2005 11 : 7391 400.
5. Toyoda H, Kumada T, Kiriyama S et al. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. Cancer 2004 100 : 2415 21.
6. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001 35 : 421 30.
7. Papatheodoridis GV, Dimou E, Dimakopoulos K et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005 42 : 121 9.
8. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124 : 105 17.
9. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001 34 : 411 16.
10. Bae SH, Yoon SK, Choi JY et al. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis. J. Gastroenterol. Hepatol. 2005 20 : 1527 32.
11. Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J. Viral. Hepat. 2005 12 : 386 92.
12. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000 31 : 207 10.
13. Kapoor D, Guptan RC, Wakil SM et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J. Hepatol. 2000 33 : 308 12.
14. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004 127 : S303 9.
15. Kubo S, Hirohashi K, Tanaka H et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000 88 : 1016 24.
16. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004 351 : 1521 31.
17. Matsumoto A, Tanaka E, Rokuhara A et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B. A multicenter retrospective study of 2795 patients. Hepatol. Res. 2005 32 : 173 84.
18. Piao CY, Fujioka S, Iwasaki Y et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma - using an untreated, matched control cohort. Acta Med. Okayama 2005 59 : 217 24.
19. Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer, 1st English edn. Tokyo : Kanehara & Company, 1997.
20. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999 29 : 971 5.
21. Lampertico P, Del Ninno E, Vigano M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003 37 : 756 63.
22. van Zonneveld M, Honkoop P, Hansen BE et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004 39 : 804 10.
23. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J. Hepatol. 2001 34 : 593 602.
24. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 : 65 73.
25. Sakon M, Umeshita K, Nagano H et al. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch. Surg. 2000 135 : 1456 9.
26. Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2002 17 : S333 7.
27. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005 42 : 1414 19.